Page 12 - 《中国药房》2023年1期

方药注册程序。（3）完善配套政策体系，制定指导企业开 [ 9 ] Health Canada. About natural health products[EB/OL].
展非处方药研发的分类管理指南，引导和鼓励非处方药 [2022-03-14]. https：//www.canada.ca/en/health-canada/
的申请和创新，促进制药行业的发展。另外，加拿大对 services/drugs-health-products/natural-non-prescription/
“传统药物”及“顺势疗法药物”建立了一套特殊的管理 regulation/about-products.html#a6.
模式，这种模式虽然不适用于我国，但是对于传统中药 [10] NAPRA. Background on update to NAPRA NHP policy
[EB/OL]. （2022-01-19）[2022-07-06]. https：//napra.ca/
的管理有一定的借鉴价值。我国不能完全参照化学药
background-update-napra-nhp-policy.
类非处方药的模式管理中药非处方药，药品监管部门可
[11] Laws Justice. Natural health products regulations[EB/OL].
建立和发布中药非处方药规范化技术标准或指导性文
（2022-02-18） [2022-07-12]. https：//laws. justice. gc. ca/
件，以更好地指导企业研发和生产中药类非处方药产
eng/regulations/sor-2003-196/index.html.
品，同时充分考虑中药类非处方药在注册和转换中的特
[12] Health Canada. Switching a medicinal ingredient from
殊性，支持和发展我国中药类非处方药，为中药国际化 prescription to non-prescription status draft guidance
竞争创造优势。 document[EB/OL]. （2022-04-21）[2022-07-13]. https：//
参考文献 www. canada. ca/en/health-canada/programs/consultation-
[ 1 ] 朱兰，邵波，夏东胜.我国遴选与转换中成药非处方药概 draft-revised-guidance-switching-medicinal-ingredient-
况及思考[J].中国药物警戒，2020，17（11）：785-789. prescription-non-prescription/contact-information-glos-
[ 2 ] Health Canada. Natural and non-prescription health pro- sary.html.
ducts directorate[EB/OL]. （2020-03-05）[2022-07-12]. [13] Health Canada. Non-prescription drugs：category Ⅳ
https：//www.canada.ca/en/health-canada/corporate/about- monographs[EB/OL]. （2016-01-26）[2022-07-13]. https：//
health-canada/branches-agencies/health-products-food- www.canada.ca/en/health-canada/services/drugs-health-
branch/natural-non-prescription-health-products-directo- products/drug-products/applications-submissions/guidance-
rate.html. documents/non-prescription-drugs-category-iv-monographs.
[ 3 ] NAPRA. Drug scheduling in Canada：general overview html.
[EB/OL]. （2022-07-06）[2022-07-12]. https：//www.napra. [14] NAPRA. Rules of procedure[EB/OL].（2009-01-29）
ca/drug-scheduling-canada-general-overview. [2022-07-13]. https：//www.napra.ca/sites/default/files/
[ 4 ] Health Canada. Classification of products under the Food documents/NDSAC_Rules_of_Procedure.pdf.
and Drugs Act （F&DA）[EB/OL]. （2022-03-29）[2022-07- [15] NAPRA. Application for drug scheduling[EB/OL]. （2022-
12]. https：//www.canada.ca/en/health-canada/services/ 07-06）[2022-07-13]. https：//www.napra.ca/application-
drugs-health-products/classification-products-food-drug- drug-scheduling.
sact.html. [16] NAPRA. National drug scheduling factors[EB/OL].
[ 5 ] Laws Justice. Food and drug act [EB/OL]. （2021-05-06） （2017-09-26）[2022-07-13]. https：//www.napra.ca/sites/
[2022-07-12]. https：//laws.justice.gc.ca/eng/acts/f-27/ default/files/documents/NDSAC_Scheduling_Factors_
index.html. website_September2017.pdf.
[ 6 ] Health Canada. Regulation of non-prescription drugs[EB/ [17] NAPRA. Supplemental standards of practice Ⅱ and Ⅲ
OL]. [2022-03-22]. https：//www.canada.ca/en/health- [EB/OL]. （2005-8-12）[2022-07-13]. https：//www. napra.
canada/services/self-care-regulation-non-prescription- ca/sites/default/files/documents/SupplementalStandardsof-
drugs.html. PracticeⅡandⅢ-June 2005.pdf.
[ 7 ] LEELAVANICH D，ADJIMATERA N，BROESE VAN [18] NAPRA. NDS Process and scheduling factors[EB/OL].
GROENOU L，et al. Prescription and non-prescription （2022-07-06）[2022-07-13]. https：//www.napra.ca/nds-
drug classification systems across countries：lessons process-and-scheduling-factors.
learned for Thailand[J]. Risk Manag Healthc Policy， [19] NAPRA. Conditions of sale for each drug schedule[EB/
2020，13：2753-2768. OL]. （2009-01-30）[2022-07-13]. https：//www.napra.ca/
[ 8 ] 世界各国的保健食品监管[EB/OL]. （2017-08-22）[2022- sites/default/files/documents/Schedules-Outline.pdf.
07-06]. http：//chinawto.mofcom.gov.cn/article/jsbl/zszc/ （收稿日期：2022-07-20 修回日期：2022-10-31）
201708/20170802631073.shtml. （编辑：刘明伟）

· 6 · China Pharmacy 2023 Vol. 34 No. 1 中国药房 2023年第34卷第1期